Arvinas (Arvinas) Additional Paid-In Capital : $2,016.10 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arvinas Additional Paid-In Capital?

Arvinas's quarterly additional paid-in capital increased from Sep. 2023 ($1,644.20 Mil) to Dec. 2023 ($1,995.70 Mil) and increased from Dec. 2023 ($1,995.70 Mil) to Mar. 2024 ($2,016.10 Mil).

Arvinas's annual additional paid-in capital increased from Dec. 2021 ($1,469.20 Mil) to Dec. 2022 ($1,549.40 Mil) and increased from Dec. 2022 ($1,549.40 Mil) to Dec. 2023 ($1,995.70 Mil).

Arvinas Additional Paid-In Capital Historical Data

The historical data trend for Arvinas's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arvinas Additional Paid-In Capital Chart

Arvinas Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

599.10

1,133.50

1,469.20

1,549.40

1,995.70

Arvinas Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,570.80	1,589.60	1,644.20	1,995.70	2,016.10

Arvinas Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Arvinas Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Arvinas's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Arvinas (Arvinas) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511

Website

https://www.arvinas.com

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Executives

Ronald Peck	officer: Chief Medical Officer	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal	director	60 LEVERONI COURT, NOVATO CA 94949
Ian Taylor	officer: Senior Vice President, Biology	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston	director, officer: President and CEO	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy	officer: Chief Financial Officer	322 EAST MAIN STREET, BRANFORD CT 06405
Everett Cunningham	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
David K Loomis	officer: Chief Accounting Officer	C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
John D Young	director	C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe	director, 10 percent owner	C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon	director	C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr.	director	C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon	director
Linda Bain	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139